TrialGynecologic oncology2007

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

D Scott McMeekin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.